AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

AstraZeneca PLCNYSE: AZN

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income growth accelerates

Q3 FY2026 net income of $3.08B rose 21.4% year over year, ahead of the +15.4% change in trailing-twelve-month net income. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at +59.9% a year.

Context

  • Net income amounted to 17.4% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 18 analysts of $15.91B (+55.6%) for the fiscal year ending Dec 2026, a step up from the +17.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$3.08B+24.2% QoQ
Last fiscal yearDec 2025
$10.23B+17.7% YoY
LTMSep 2026
$11.82B+15.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.4%+53.4%+31.9 pp
1 year+17.7%+55.6%+38.0 pp
3-year CAGR+59.9%+24.5%-35.4 pp
5-year CAGR+19.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
10.23B USD
Year-over-year change
+17.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.4% is the 5th highest of 10, against a peer median of +4.8%.
  • Net income amounts to 19.0% of revenue for AZN, versus a peer median of 18.9%.
AZN Competitors
Net Income for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.27B USD+83.1%+3.6%18.9%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding AZN) —+4.8%+7.9%18.9%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265M)2.5B6.9B8.69B10.23B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
Deferred Income Tax(615M)(619M)000
Stock-Based Compensation615M619M579M00
Change in Working Capital2.02B3.76B300M(893M)(1.16B)
Accounts Receivables(961M)(1.35B)(1.43B)(1.62B)0
Inventory1.58B3.94B(669M)(131M)0
Accounts Payables961M1.35B1.43B00
Other Working Capital444M(184M)969M862M(1.16B)
Other Non-Cash Items105M(1.7B)(2.37B)(1B)(220.71M)
Operating Cash Flow5.96B9.81B10.35B11.86B14.58B
Capital Expenditures(2.2B)(2.57B)(3.78B)(4.59B)(5.91B)
Acquisitions (Net)(9.43B)(1.06B)(1.18B)(3.93B)(1.24B)
Purchases of Investments(184M)(159M)(136M)(96M)(229M)
Sales of Investments105M42M129M108M131M
Other Investing Activities654M789M(1.52B)(2.14B)(2.66B)
Investing Cash Flow(11.06B)(2.96B)(4.06B)(7.98B)(6.81B)
Debt Repayment7.89B(1.2B)(965M)1.81B(1.65B)
Common Stock Issued29M29M33M(43M)(481M)
Common Stock Repurchased00000
Dividends Paid(3.86B)(4.36B)(4.48B)(4.63B)(4.97B)
Other Financing Activities(418M)(1.29B)(1.15B)(1.13B)(442M)
Financing Cash Flow3.65B(6.82B)(6.57B)(4B)(7.54B)
Effect of Forex Changes(62M)(80M)(60M)(93M)46M
Net Change in Cash(1.51B)(55M)(346M)(208M)269M
Free Cash Flow3.76B7.24B6.57B7.28B8.67B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.